Overview

* BioStem Q3 2025 revenue fell 43% yr/yr

* Net income for Q3 2025 was $0.8 mln compared to $6.8 mln a year earlier

* Company's gross profit margin improved to 88.5% from 77% in Q3 2024

Outlook

* BioStem expects top-line readout for BioREtain venous leg ulcer trial in Q1 2026

* Company plans to launch American Amnion product in Q4 for VA partnership

* BioStem ( BSEM ) cites reimbursement uncertainty and competition as challenges for wound care

Result Drivers

* PRODUCT VOLUME GROWTH - Achieved 40% growth in product volume quarter-over-quarter

* GROSS PROFIT MARGIN - Improved gross profit margin due to product mix shift towards products without licensing fees

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $10.50 $51.30

Revenue mln mln (1

Analyst)

Q3 EPS $0.03

Q3 Net Miss $800,000 $4.63

Income mln (1

Analyst)

Analyst Coverage

* Wall Street's median 12-month price target for Biostem Technologies Inc ( BSEM ) is $25.50, about 81.8% above its November 12 closing price of $4.65

* The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)